AIMS: To examine heterogeneity in outcome following treatment for smoking cessation with combined bupropion SR and behavioral counseling in women and men. DESIGN, SETTING, PARTICIPANTS: This study included 875 women and 649 men recruited from a large health-care system and randomized to one of four combinations of treatment [two dosage levels ofbupropion SR (Zyban, 150 mg and 300 mg) were crossed with two counseling programs of lower and higher intensity to create a four-cell design]. MEASUREMENTS AND FINDINGS: A comprehensive set of relevant individual characteristics prior to treatment and treatment characteristics was included in the analysis. Smoking outcome at 12 months was defined as point-prevalence of any regular smoking within the 7 days prior to follow-up contact. Classification and regression tree analysis identified six subgroups in women that ranged in proportion of non-smokers from 9.8% to 42.9% and six subgroups in men that ranged in proportion of non-smokers from 17.3% to 50.0%. CONCLUSIONS: These results indicate the presence of a substantial amount of variation in treatment outcome among women and men receiving combined bupropion SR and counseling. Variation in outcome could be reduced by providing treatments tailored to subgroups of individuals who are at exceptionally high risk for smoking following cessation.
RCT Entities:
AIMS: To examine heterogeneity in outcome following treatment for smoking cessation with combined bupropion SR and behavioral counseling in women and men. DESIGN, SETTING, PARTICIPANTS: This study included 875 women and 649 men recruited from a large health-care system and randomized to one of four combinations of treatment [two dosage levels of bupropion SR (Zyban, 150 mg and 300 mg) were crossed with two counseling programs of lower and higher intensity to create a four-cell design]. MEASUREMENTS AND FINDINGS: A comprehensive set of relevant individual characteristics prior to treatment and treatment characteristics was included in the analysis. Smoking outcome at 12 months was defined as point-prevalence of any regular smoking within the 7 days prior to follow-up contact. Classification and regression tree analysis identified six subgroups in women that ranged in proportion of non-smokers from 9.8% to 42.9% and six subgroups in men that ranged in proportion of non-smokers from 17.3% to 50.0%. CONCLUSIONS: These results indicate the presence of a substantial amount of variation in treatment outcome among women and men receiving combined bupropion SR and counseling. Variation in outcome could be reduced by providing treatments tailored to subgroups of individuals who are at exceptionally high risk for smoking following cessation.
Authors: Roland Pesch; Hendrik Pehlke; Kerstin Jerosch; Winfried Schröder; Michael Schlüter Journal: Environ Monit Assess Date: 2007-08-07 Impact factor: 2.513
Authors: Harold S Javitz; Terry M Bush; Jennifer C Lovejoy; Alula J Torres; Tallie Wetzel; Ken P Wassum; Marcia M Tan; Nabil Alshurafa; Bonnie Spring Journal: Ann Behav Med Date: 2019-11-09
Authors: Nicole L Nollen; Jasjit S Ahluwalia; Yang Lei; Qing Yu; Taneisha S Scheuermann; Matthew S Mayo Journal: Nicotine Tob Res Date: 2015-05-20 Impact factor: 4.244
Authors: Terry Bush; Michele D Levine; Mona Deprey; Barbara Cerutti; Susan M Zbikowski; Tim McAfee; Lisa Mahoney; Laura Beebe Journal: J Smok Cessat Date: 2008-12-01
Authors: Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll Journal: Addict Behav Date: 2017-07-12 Impact factor: 3.913
Authors: Terry M Bush; Michele D Levine; Brooke Magnusson; Yu Cheng; Xiaotian Chen; Lisa Mahoney; Lyndsay Miles; Susan M Zbikowski Journal: Ann Behav Med Date: 2014-04